- Home
- GERN vs HOV Comparison
GERN vs HOV Comparison
Compare GERN & HOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- HOV
- Stock Information
- Founded
- GERN 1990
- HOV 1959
- Country
- GERN United States
- HOV United States
- Employees
- GERN 229
- HOV N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- HOV Homebuilding
- Sector
- GERN Health Care
- HOV Consumer Discretionary
- Exchange
- GERN Nasdaq
- HOV Nasdaq
- Market Cap
- GERN 823.0M
- HOV 877.2M
- IPO Year
- GERN 1996
- HOV N/A
- Fundamental
- Price
- GERN $1.30
- HOV $151.96
- Analyst Decision
- GERN Buy
- HOV Sell
- Analyst Count
- GERN 8
- HOV 2
- Target Price
- GERN $3.71
- HOV $120.00
- AVG Volume (30 Days)
- GERN 6.6M
- HOV 101.9K
- Earning Date
- GERN 11-06-2025
- HOV 08-21-2025
- Dividend Yield
- GERN N/A
- HOV N/A
- EPS Growth
- GERN N/A
- HOV N/A
- EPS
- GERN N/A
- HOV 20.64
- Revenue
- GERN $164,447,000.00
- HOV $3,140,315,000.00
- Revenue This Year
- GERN $175.15
- HOV N/A
- Revenue Next Year
- GERN $56.61
- HOV $2.74
- P/E Ratio
- GERN N/A
- HOV $7.55
- Revenue Growth
- GERN 11877.20
- HOV 7.83
- 52 Week Low
- GERN $1.09
- HOV $81.15
- 52 Week High
- GERN $4.83
- HOV $233.15
- Technical
- Relative Strength Index (RSI)
- GERN 42.28
- HOV 58.04
- Support Level
- GERN $1.27
- HOV $145.10
- Resistance Level
- GERN $1.52
- HOV $156.01
- Average True Range (ATR)
- GERN 0.06
- HOV 5.14
- MACD
- GERN -0.02
- HOV -0.00
- Stochastic Oscillator
- GERN 8.00
- HOV 77.43
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About HOV Hovnanian Enterprises Inc.
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.